DAX®11.560,51-4,17%TecDAX®2.829,31-2,92%Dow Jones 3026.646,98-2,97%Nasdaq 10011.230,73-3,17%
finanztreff.de

DGAP-Adhoc: Epigenomics AG: U.S. Centers for Medicare & Medicaid Services publish negative proposed NCD for Epi proColon

| Quelle: Dow Jones Newsw... | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-Ad-hoc: Epigenomics AG / Key word(s): Miscellaneous
Epigenomics AG: U.S. Centers for Medicare & Medicaid Services publish
negative proposed NCD for Epi proColon

17-Oct-2020 / 00:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*U.S. Centers for Medicare & Medicaid Services publish negative proposed NCD
for Epi proColon*

*Berlin, October 16, 2020-* Epigenomics AG (Frankfurt Prime Standard: ECX,
OTCQX: EPGNY; the "Company") announces that the U.S. Centers for Medicare &
Medicaid Services (CMS) have issued a negative reimbursement proposal in
connection with the National Coverage Determination (NCD) of Epi proColon,
Epigenomics' blood test for colorectal cancer screening.

The proposed NCD is preliminary. According to the statutes, a 30-day public
comment period will now begin, which will be used to further convince CMS of
the benefits of Epi proColon in the fight against colorectal cancer. The
public response during the initial public comment period at the beginning of
the NCD was overwhelmingly positive. Following the comment period, CMS will
publish their final decision within 60 days. If the final decision is also
negative, the Company will take the opportunity to appeal the decision.

*Contact:*
*Company*
Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, e-mail:
contact@epigenomics.com

*Investor Relations*
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, e-mail: ir@epigenomics.com

*Forward-Looking Statements*

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any expected
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events or
otherwise.

17-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 1141448

End of Announcement DGAP News Service

1141448 17-Oct-2020 CET/CEST



(END) Dow Jones Newswires

October 16, 2020 18:03 ET ( 22:03 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Glauben Sie, dass sich der SAP-Kurs nach dem Kursrutsch von gestern bis Ende des Jahres wieder erholen wird?
Jetzt abstimmen!
Alle Umfragen ansehen